The scientists at BSRC “Alexander Fleming” perform cutting-edge research, aiming to understand molecular mechanisms of complex biological processes in health and disease. We are also committed to contribute to innovation in medicine, by developing novel therapeutic and diagnostic methods, focusing on immunity and inflammation, cancer, and neurodegenerative diseases. To keep our focus on top-notch research, we recruit at all levels with excellence as the sole criterion and we support our researchers by providing state-of-the science infrastructures and a pleasant working environment. FLEMING is a non-profit organization operating under the auspices of the Greek General Secretariat for Research & Technology and is supported by the Greek government and by national, European and international grants.
Expanding previous work on the role of autotaxin in chronic inflammatory disorders that have led to phase II clinical trials in idiopathic pulmonary fibrosis, Fleming researchers have now uncovered a novel, major role for this secreted lysophospholipase D in the pathogenesis of hepatitis and hepatocellular carcinoma. PubMed.
Fleming Researcher Dr Antigone Dimas has been awarded an ERC Starting Grant to explore the complex biological impact of dietary intake in humans. This is the fourth ERC grant awarded to a Fleming Researcher in the past 5 years. The title of Dr Dimas's grant is "A genomics and systems biology approach to explore the molecular signature and functional consequences of long-term, structured fasting in humans”.
Recent work by Fleming researchers identifies a Wnt-regulated long non-coding RNA that controls intestinal stem cell fate and carcinogenesis. Pubmed
Seminar 31/03/2017, 13.00. "Lessons from the Rare Genetic Disease space: from novel biology to drug discovery", Aris N. Economides, Ph.D., Vice President - Research, Regeneron Pharmaceuticals, Inc.